Alcon Science

During #microsurgery, retinal surgeons rely on exacting precision and control to operate at a microscopic scale. As such, the utility of microsurgical instrument handles can be significantly affected by: ➡️ Angular orientation ➡️ Handle diameter ➡️ Actuation forces ➡️ Instrument stiffness Years of painstaking effort has been exerted to optimize microsurgical instrument handles to suit surgeons from different regions, genders, hand sizes and experience levels. Learn more about the evolution of these essential tools in our #WhitePaper, Factors Influencing The Design Of Microsurgical Instrument Handles: bit.ly/3Z4yEN7 #EyeCare #Ophthalmology #AlconScience #GlobalMedicalAffairs #MedicalAffairs #SurgicalRetina

Here, Dr. Debbie Kuo introduces a study on the Outcomes of #CataractSurgery and Hydrus® Microstent Implantation in Asian Eyes with Normal Tension #Glaucoma. This retrospective cohort study analyzed: ✅ Medication reduction from baseline at 1 year and subsequent years ✅ Mean intraocular pressure (IOP) change from baseline ✅ Proportion of eyes meeting IOP targets ✅ Percentage of eyes requiring secondary surgical intervention at yearly timepoints Explore these findings now in the full study summary video: bit.ly/4qRrEiJ #GlaucomaAwarenessMonth #Ophthalmology #GlobalMedicalAffairs #MedicalAffairs #Alcon #AlconInnovation #AlconScience

Understanding why patients discontinue contact lens wear remains essential to supporting long‑term success. Our Alcon Medical Affairs backgrounder, "Managing Contact Lens Dropout With Water Gradient Contact Lenses", reviews key factors associated with dropout and outlines evidence‑based considerations for managing patients who have discontinued or are at risk. 👁️ Discomfort, dryness, and suboptimal vision continue to be leading contributors to dropout, with retention varying across optical designs—from spherical to toric and multifocal lenses. 🔬 Evidence indicates that patients who previously discontinued lens wear can often succeed when refit in options that better address their ocular needs and expectations. 💧 Water Gradient contact lenses—combining a silicone hydrogel core with a surface approaching nearly 100% water—are designed to deliver a highly wettable, lubricious interface that may help support comfort in both patients who have dropped out of contact lens wear and those at risk of dropout. 👉Explore the full scientific summary and clinical evidence here: alconscience.com/resource/manag…

📣 Did you know: #DryEye phase 3 study results are in for topical acoltremon 0.003% (ACO)! Previously, a large, phase 2b study showed this transient receptor potential melastatin 8 (TRPM8) agonist — originally known as AR-15512 — led to a rapid increase in tear production and reduction in dry eye disease (#DED) symptoms. In this video, Dr. Walter Whitley reviews key findings from a presentation — Tear Production Associated With a Novel TRPM8 Agonist (AR-15512): Results From Phase 3 Pivotal Clinical Studies (COMET-2 and COMET-3) — which summarized pivotal efficacy and safety data from the Phase 3 studies conducted on acoltremon 0.003% To see the results, watch the full video: bit.ly/44EQA4h Here’s a quick preview: 📌 The primary endpoint (proportion of subjects with a ≥10 mm increase in unanesthetized Schirmer score at day 14), was met in both studies 📌 Tear production was observed as early as after the first dose and continued through day 90 📌 Exploratory finding suggest reductions in total corneal and total conjunctival staining as early as Day 7 Tap the link above to watch the full study summary video from Alcon #GlobalMedicalAffairs on AlconScience.com. #Ophthalmology #AlconScience #AlconInnovation #MedicalAffairs

🔍 Streamline your product research with ALMI, our Alcon medical information virtual assistant— delivering fast, reliable answers on #Alcon products when you need them. ALMI makes it easy to find accurate answers to common questions about safety, indications, product specifications, and packaging guidance, so you can spend more time focusing on patient care. Chat with ALMI now on the Medical Information section of #AlconScience.com: bit.ly/4p7s0jS #GlobalMedicalAffairs #EyeCare #MedicalInformation

Burning, itching, stinging, grittiness…The physical discomfort of #DryEye disease (#DED) is well documented. But DED can also make it difficult to perform daily activities and maintain productivity at work. In this video, Dr. Cory Lappin introduces a study evaluating the potential impact of a novel DED treatment on activities like driving, reading, using electronic devices and watching TV, as well as on work productivity. ➡️ Watch the full study summary video here: bit.ly/4pNz7iF The study — titled Improvement in Visual Tasking Activities and Workplace Productivity After 14 Days of Acoltremon 0.003% (ACO) Treatment: Integrated Analysis of COMET Studies — found that patients demonstrated rapid and consistent improvements in activities associated with visual tasking and workplace productivity. Tap the link above to watch the full study summary video from Alcon #GlobalMedicalAffairs on AlconScience.com. #Ophthalmology #AlconScience #AlconInnovation #MedicalAffairs

Can #ContactLens dropouts who stopped wearing their lenses due to discomfort be successfully re-fit in TOTAL30® lenses from #Alcon? Drs. Chris Lievens and Andrew Pucker present highlights and results from a study on this topic here: bit.ly/4qfRL2n The prospective, 3-site, single-arm, non-comparative study — Evaluating the Frequency of Comfortably Refitting Contact Lens Dropouts into a Monthly Replacement Soft Contact Lens— was designed to assess: 🔹The percentage of past contact lens wearers comfortably wearing TOTAL30® lenses at 1 month 🔹Overall satisfaction, vision and end-of-day comfort while wearing TOTAL30® lenses 🔹Likelihood of continuing to wear and recommending TOTAL30® lenses after 1 month 🔹Standardized patient evaluation of eye dryness symptoms and visual acuity Tap the link above to watch the full video from Alcon #GlobalMedicalAffairs on AlconScience.com. #Ophthalmology #AlconScience #AlconInnovation #MedicalAffairs

The new #AlconScience #Eyetube portal features #Ophthalmology videos spanning 8 filterable therapeutic areas — including #CataractSurgery equipment and diagnostics, #ContactLenses and #DryEye pharmaceuticals. Here’s a sneak peek at what you’ll find under OTC #OcularHealth: bit.ly/43JFdHz #Alcon #GlobalMedicalAffairs

As we prepare for the Southeastern Educational Congress of Optometry 2026, Alcon Global Medical Affairs looks forward to facilitating evidence‑based discussions throughout the meeting. 📅 During February 25–March 1, we will be available for Scientific Exchange presentations focused on emerging data and clinical considerations relevant to optometric care: 1⃣️ Acoltremon Ophthalmic Solution 0.003% Overview 2⃣ Importance of Maintaining Physiologic Aqueous Outflow in Glaucoma: Surgical and Pharmaceutical Approaches ️We welcome HCPs attending #SECO2026 to join these peer‑to‑peer scientific sessions. Register here and visit us at Booth #223 for additional information on our presence during the congress. tinyurl.com/AlconMedicalAf… #SECO2026 #ScientificExchange #MedicalEducation #Optometry #GlobalMedicalAffairs

Meet Alcon Medical Affairs at SECO 2026 for an evening scientific program. ️Importance of Maintaining Physiologic Aqueous Outflow in Glaucoma: Surgical and Pharmaceutical Approaches 📍 Location: Ruth’s Chris Steak House, Embassy Suites Hotel, 267 Marietta St NW Atlanta, GA 📅 Date: Friday, February 27, 2026 🕕 Time: 8:00 PM (EST) Join Alcon Medical Affairs for an in‑depth overview of the Importance of Maintaining Physiologic Aqueous Outflow in Glaucoma: Surgical and Pharmaceutical Approaches. Connect with our team as we explore current scientific perspectives and clinical considerations for practice. ➡️ Registration: go.alconexchangeportal.com/register/1/c07… #AlconScience #MedicalAffairs #DryEye #DryEyeDisease #Acoltremon #Ophthalmology #Optometry #SECO2026 #HCPs

Meet Alcon Medical Affairs at SECO 2026 for an evening of scientific discussion. ️Acoltremon Ophthalmic Solution 0.003% Overview 📍 Location: Ruth’s Chris Steak House, Embassy Suites Hotel, 267 Marietta St NW Atlanta, GA 📅 Date: Friday, February 27, 2026 🕕 Time: 6:15 PM (EST) Join Alcon Medical Affairs for an in‑depth overview of acoltremon ophthalmic solution 0.003%, with a focus on its role in the management of Dry Eye Disease. Connect with our team as we explore current scientific perspectives and clinical considerations for practice. ➡️ Registration: go.alconexchangeportal.com/register/1/0e2… #AlconScience #MedicalAffairs #DryEye #DryEyeDisease #Acoltremon #Ophthalmology #Optometry #SECO2026 #HCPs

Alcon Medical Affairs invites you to join our poster presentations at the American Glaucoma Society Annual Meeting: 📆Thursday, February 19: ➡️Three-Year Outcomes of Combined Microstent and Canaloplasty with Cataract Surgery in Open-Angle Glaucoma ➡️Outcomes In Moderate OAG Patients Undergoing Visco-canaloplasty Vs Visco-canaloplasty Plus Microstent ➡️Long-Term Safety Evaluation of Eyes Treated with Direct Selective Laser Trabeculoplasty 📆Saturday, February 21: ➡️Effect of the Addition of Netarsudil 0.02% Compared to Brimonidine 0.1% in Normal Tension Glaucoma Patients Currently on Latanoprost 0.005% 📍 Location: Starlight Terrace 🕖 Time: 7:30 AM – 8:30 AM #MedicalEducation #AGS2026 #GlobalMedicalAffairs #Glaucoma

As a potent and highly selective TRPM8 agonist, acoltremon ophthalmic solution 0.003% is the first-in-class topical neuromodulator indicated for the treatment of the signs and symptoms of DED. Explore further information about TRYPTYR® at: bit.ly/489x9Rn #AlconScience #GlobalMedicalAffairs

From protecting ocular structures to reducing patient discomfort, the potential benefits of performing #CataractSurgery at a lower, intraoperative intraocular pressure (IOP) setting are supported by a growing body of clinical evidence. Watch Dr. Hisaharu Suzuki summarize full study details and results here ➡️bit.ly/4oVKdkZ⬅️ In a recent study titled Anterior Chamber Stability of a Novel Phacoemulsification Machine via the Slit Side View Method, Dr Suzuki evaluated both the UNITY® Vitreoretinal Cataract System and the Centurion® Vision System with Active Sentry® during simulated occlusion breaks at various IOP settings. Dr. Suzuki observed that the Unity VCS, featuring real-time sensing and independently controlled aspiration and irrigation, achieved a 2.8-fold improvement in chamber stability compared to Centurion Active Sentry. Learn about other outcomes, including maximum variability for all settings, in the full video from the #Alcon #GlobalMedicalAffairs team on #AlconScience.com via the link above. #MedicalAffairs #ClinicalStudy

👁️ To help relieve the symptoms of #DryEye disease (#DED), acoltremon 0.003% (ACO) was formulated to stimulate cold-sensing nerve endings that trigger basal tear secretion. In the insight video below, Dr. Nate Lighthizer introduces a study of this novel treatment, titled acoltremon 0.003% Leads to a Statistically Significant Increase in Tear Volume and Tear Total Lipid Concentration: Phase 3b Study Results. The study aimed to quantify: 💧ACO-stimulated tear volume using non-invasive optical coherence tomography imaging of the central tear meniscus height 💧The concentration of total lipids in ACO-stimulated tears The results? Investigators found that even a single dose of ACO led to a statistically significant increase in tear volume — and statistically significantly greater tear total lipid concentration. For more study details and results, watch the full summary video from #Alcon #GlobalMedicalAffairs here: bit.ly/48WpRBn #Ophthalmology #AlconScience #AlconInnovation #MedicalAffairs

As we prepare for the American Glaucoma Society 2026 meeting (February 19–22), our Global Medical Affairs team looks forward to facilitating in‑depth scientific discussions throughout the congress. We will host a series of Scientific Exchange presentations focused on clinical evidence, emerging insights, and considerations for glaucoma management. Sessions include: ✅Rhopressa Clinical Summary ✅Rocklatan Summary of Phase 3 and 4 Clinical Efficacy and Safety ✅Netarsudil and Netarsudil/Latanoprost Efficacy in Black vs White Individuals ✅Direct Selective Laser Trabeculoplasty in the Treatment of Open Angle Glaucoma ✅Importance of Maintaining Physiologic Aqueous Outflow in Glaucoma: Surgical and Pharmaceutical Approach ➡️If you are attending #AGS2026, we welcome you to join these peer‑to‑peer scientific discussions and register for a session here: shorturl.at/IWUGd #ScientificExchange #AGS2026 #MedicalEducation #GlobalMedicalAffairs #Glaucoma

🥼With the Southeastern Educational Congress of Optometry approaching, our Global Medical Affairs team looks forward to joining peers in Atlanta for a week of scientific dialogue and evidence‑based learning. 📩 We invite you to connect with us at SECO 2026, where we will host Scientific Exchange presentations and a live scientific discussion focused on emerging data and clinical considerations in optometric care. Visit us at Booth #223 at the Georgia World Congress Center from February 25–March 1 to meet our team and learn more about our scientific programming. More details on our Scientific Exchange sessions and discussion event will follow. #SECO2026 #ScientificExchange #MedicalEducation #Optometry #GlobalMedicalAffairs

How do different types of presbyopia-correcting #IntraocularLenses (#IOLs) actually work? Read the Alcon Medical Affairs #WhitePaper to find out: bit.ly/4rUdoXu In the white paper, titled Refractive and Diffractive Principles in Presbyopia-Correcting IOLs — An Optical Lesson, you’ll discover: 🔹 How refractive and diffractive optical approaches achieve multifocality in IOLs 🔹 How trifocal IOLs can utilize various diffractive optical designs to create distance, intermediate and near focal points #EyeCare #Ophthalmology #AlconScience #GlobalMedicalAffairs #MedicalAffairs

Alcon Medical Affairs invites you to attend a live scientific discussion during the American Glaucoma Society 2026 meeting, focused on the Importance of Maintaining Physiologic Aqueous Outflow in Glaucoma: Surgical and Pharmaceutical Approaches. 🧬🧬 This session will explore evolving insights into aqueous outflow physiology and review both surgical and pharmaceutical strategies that support clinical decision‑making in glaucoma management. 📍 Location: Mastro’s Steakhouse, 73405 El Paseo, Suite 120 Palm Desert, California 📅 February 19, 2026 Time: 6:00 PM PST We look forward to an engaging evening of peer‑to‑peer scientific exchange and evidence‑based discussion. Space is limited, and early registration is encouraged for those planning to attend go.alconexchangeportal.com/register/1/116… #ScientificExchange #MedicalEducation #AGS2026 #GlobalMedicalAffairs #Glaucoma

💧 Tear-replenishing eye drops are often a go-to treatment for #DryEye disease (#DED). But the relief they bring tends to be short-lived. A recent #ClinicalStudy, introduced here by Dr. Katherine Bickle, analyzed the efficacy of a novel, lipid-based eye drop designed to enhance tear film stability, improve water retention and extend DED symptom relief. See the full study summary video here: bit.ly/49jvNWs The study — titled Rapid, Lasting Relief of Dry Eye Symptoms with Propylene Glycol-Hydroxypropyl-Guar-Hyaluronic Acid Nanoemulsion Lubricant Preservative-Free Eye Drops — showed that this novel formulation provided: 🔹 Rapid and lasting relief of mild to moderate DED symptoms 🔹 A ≥7-point symptom improvement that lasted up to 12 hours in nearly half of patients Tap the link above to watch the full video from our #GlobalMedicalAffairs team on AlconScience.com. #Ophthalmology #Alcon #AlconScience #AlconInnovation #MedicalAffairs